Tuesday, 24 April 2018 - 0:15
  • it
  • de
  • en
  • fr

Amgen

US groups stronger and more competitive thanks to fiscal reform

The JP Morgan Healthcare Conference, which has just ended in San Francisco, has given analysts an opportunity to analyze the different views of big pharma companies’ CEOs . The fiscal reform proposed by the Trump administration has been a widely-debated…

Amgen announces Phase III results from migraine therapy

Amgen yesterday reported that The New England Journal of Medicine had published results from the Phase III STRIVE clinical trial, assessing the investigational drug Aimovig (erenumab) vs placebo for the prevention of chronic migraine. Aimovig is a monoclonal antibody that…

M&A drive in pharma fading

Deals in pharma M&A in the first 9 months of the year totaled $66.4bn, equaling a 36% drop as compared to 2016. The decrease is even more significant when compared to 2015, when sales volume over the first three quarters…

New spate of job cuts: Amgen and Genentech announce 330 layoffs

Amgen is starting a large restructuring plan, especially affecting its Californian headquarters in Thousand Oaks, currently employing approximately 5,000 people. The plan will result in an immediate cut of approximately 200 R&D jobs. Amgen announced a reorganization concerning 500 Thousand…

Novartis, Amgen and Banner Alzheimer’s Institute, cooperation broadened

Novartis, Amgen and Banner Alzheimer’s Institute (BAI) have announced they have broadened their cooperation. Specifically, the companies have informed they will initiate the API (Alzheimer’s Prevention Initiative) Generation Study 2, designed to assess the CNP520 BACE1 inhibitor in preventing or…

Amgen pursuing M&A again: takes control of JV Amgen-Kirin for $810m

California-based Amgen is pursuing M&A again and is using part of its liquidity to wholly acquire JV Kirin-Amgen from Japan-based partner Kirin Holdings Company, Ltd. Under the agreement, Amgen will make an upfront $780m payment, followed by a $30m payment…

Regeneron and Sanofi win legal battle against Amgen over Praluent

Regeneron and its partner Sanofi have won their legal battle against Amgen: indeed, a US appeals court yesterday reversed the former ruling preventing the two companies from marketing Praluent. Sanofi’s shares soon rose 1.8%, while Regeneron’s were up 1.6%. By…

German startup Immatics financed with $58m, funders include Amgen

The Amgen group has taken part to the $58m funding granted to Tübingen, Germany-based Immatics, in order to support research in T cells. Investors, in addition to Amgen, include Wellington Partners and other traditional investors. Immatics’ main assets are IMA101…

Amgen signs agreement with Simcere to market biosimilars in China

Biotech group Amgen has announced it has signed an agreement with China-based Simcere Pharmaceutical, aimed at developing and marketing four biosimilars in the areas of inflammation and oncology in China. Under the terms of the agreement, Amgen will remain responsible…

Boehringer Ingelheim obtains FDA approval for biosimilar to Humira

Boehringer Ingelheim has obtained approval by the FDA for Cyltezo, the biosimilar to AbbVie’s immunosuppressant Humira. Cyltezo is the first biosimilar by the Germany-based group to be approved and is fairly significant as it provides an alternative to the best-selling…

The best drug is not always a guarantee for the best financial results

Novo Nordisk demonstrated to investors and analysts that the best and most advanced drug is not always the product which ensures the best financial results. The Denmark-based pharmaceutical giant recently launched on the market Tresiba, a novel, advanced insulin for…

Positive opinion by ODAC (FDA) for two biosimilars by Amgen and Mylan

Amgen and Mylan hit a major target as they benefited from FDA’s Oncologic Drugs Advisory Committee (ODAC) positive opinion on the commercialization of two biosimilars – respectively manufactured by each company – to Roche’s cancer drugs Avastin and Herceptin. These…

Novartis strengthens position in biosimilar drug market

Switzerland-based group Novartis is strengthening its leading position in the biosimilar drug market through subsidiary Sandoz. Indeed, suffice it to say it has as many as 11 pending approval applications for biosimilars in EU and US and expects to launch…

EMA accepts application for Novartis/Amgen’s migraine treatment

Novartis announced that EMA accepted its MAA (Marketing Authorization Application) for AMG 334 (erenumab) for the prevention of migraine. The drug is an anti-CGRP monoclonal antibody which binds selectively to the CGRP receptor, believed to play a critical role in…

Pharmaceutical industry shows signs of slowdown

London-based market analysis company EvaluatePharma issued a report in which it cut its global revenue forecast (2017-2022) for drugmakers for the first time in a decade. This unexpected slowdown is mainly due to pressure by the government on the largest…

Amgen-Novartis partnership for anti-migraine drug erenumab now broadened

Novartis has announced it has expanded its partnership agreement with Amgen for AMG 334 (erenumab), an investigational product for the prevention of migraine. The two companies will co-commercialize the drug in the US. Novartis will retain exclusive commercialization rights to…

An excellent fourth quarter for Amgen, shares are up again

US-based biotech Amgen announced yesterday after stock markets closed its Q4 2016 results, together with the outlook for 2017. Sales in the fourth quarter totaled approximately $5.97bn, which represents a 7.7% growth over Q4 2015. EPS increased as well, from…

Amgen wins patent infringement case against Sanofi/Regeneron (Praluent)

A federal judge rejected the motion related to a patent infringement case between Amgen—which obtained a favorable verdict last March—and Sanofi/Regeneron, Reuters reported. Indeed, in October 2014 Amgen sought to stop sales of Praluent, a drug from the class of…

Episodic migraine, positive results for Amgen/Novartis’ AMG 334

Novartis today announced positive results from ARISE, a Phase-III trial aimed at evaluating the efficacy and safety of monthly AMG 334 (erenumab) 70mg in episodic migraine prevention in 577 patients. The study met the primary endpoint, demonstrating a statistically significant…

Chronic migraine, Phase III data for Amgen/Novartis’ antibody now presented

Novartis today announced complete Phase II results showing the fully human monoclonal antibody named AMG 334 (erenumab) produced a statistically significant reduction in monthly migraine days compared with placebo in patients with chronic migraine. Among trial participants, a significantly larger…